Expertise in
11
conditions

Michiel J. Coppens

Amsterdam, NH, NL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
11
conditions
Amsterdam, NH, NL 

Overview

Michiel Coppens practices practicing medicine in Amsterdam, Netherlands.

Mr. Coppens is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Hemophilia B, Blood Clots, Hemophilia A, and Venous Thromboembolism (VTE).

He is actively involved in clinical research, co-authoring 158 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Amsterdam, NH, Netherlands
Other Locations
Noord, NB, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Enrollment Status: Recruiting
Publish Date: January 15, 2026
Intervention Type: Drug
Study Drug: Rosuvastatin Calcium
Study Phase: Phase 3
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: March 27, 2026
Intervention Type: Genetic, Biological
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 3
View 1 Less Clinical Trial

158 Total Publications

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.
Journal: The New England journal of medicine
Published: December 08, 2025

Frequently Asked Questions about Michiel J. Coppens

Is Michiel J. Coppens a top-rated expert for Hemophilia B?

MediFind is an objective health platform that identifies experts based on real-world data. Michiel J. Coppens is classified as an Elite expert for Hemophilia B, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michiel J. Coppens participate in research or clinical trials?

Yes. Michiel J. Coppens has published 158 articles and abstracts on conditions like Hemophilia B. You can view a list of Michiel J. Coppens's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Coppens's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile